Abstract 3846
Background
Primary cancers of the appendix are rare and are frequently diagnosed after surgery for appendicitis. There is no designated staging system or evidence-based guideline for treatment. The staging and treatment of appendiceal adenocarcinoma mirror that of colon cancer. Elevated serum carcinoembryonic antigen (CEA) has been strongly associated with poor prognosis in colorectal cancer, so our study aims to first compare appendiceal cancers with tumors of the ascending colon, and then evaluate the prognostic value of CEA in appendiceal cancers.
Methods
We performed a retrospective analysis of all patients (n = 2,614) diagnosed with appendiceal adenocarcinoma from 2004 to 2014 in the National Cancer Institute’s Surveillance, Epidemiology and End Results database. All appendiceal cancer patients were designated as either elevated (C1) or normal (C0) based on the pretreatment serum CEA level. We performed univariate and multivariate analyses to compare appendiceal cancer characteristics to tumors of the ascending colon (n = 73,057), then identified independent factors associated with CEA elevation in appendiceal cancers.
Results
Upon multivariate analysis, compared to tumors of the ascending colon, appendiceal cancers are significantly more likely (P < 0.05) to have higher stage at diagnosis (OR 2.95, 1.19, 6.56 for stage 2, 3, and 4). They are less likely to have the CEA test ordered (OR 0.31). Appendiceal cancers are being diagnosed more in recent years (OR 1.90, 2.11, 1.86 for years 2012, 2013, and 2014) while colon cancer incidence is remaining the same. Compared to C0 appendiceal cancers, C1 cancers are more likely to have higher tumor grade (OR 6.56 and 5.50 for grade 2 and 3) and higher overall stage (OR 1.96, 2.44, 9.60 for stage 2, 3, and 4).
Conclusions
Though appendiceal cancers are rare, they are increasing in incidence. They are less likely than colorectal cancers to have the CEA test ordered despite CEA elevation odds ratio having no significant difference between the two cancers. Elevated CEA in appendiceal cancers is associated with later stage and higher grade. CEA levels should be checked in all appendiceal cancer patients to assist in the development of treatment strategies.
Clinical trial identification
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1322 - Surgical resection of primary tumor is prolonged survival in metastatic pancreatic neuroendocrine carcinoma
Presenter: Tingting Feng
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1714 - The Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) and North American Neuroendocrine Tumor Society (NANETS) Endorsement and Update of European Neuroendocrine Tumor Society (ENETS) Best Practice Consensus for Lung Neuroendocrine Tumors (LNET)
Presenter: Eva Segelov
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2785 - Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) in Patients with Pulmonary Carcinoid Tumours: Prevalence and Prognosis of an Under-Recognised Disease
Presenter: Aimee Hayes
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3685 - The role of modulation of Somatostatin Analogues (SSAs) in association to Peptide Receptor Radionuclide Therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) Entero-Pancreatic Neuroendocrine Cancers (EP-NETs)
Presenter: Natalie Prinzi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5179 - Prognostic Importance of Lymph Node (LN) yield after Curative Resection of GastroEnteroPancreatic NeuroEndocrineTumours (GEP NETs)
Presenter: Jaseela Chiramel
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5662 - Evaluation of the efficacy and safety of everolimus as a first-line treatment in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors
Presenter: Anna Koumarianou
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2906 - Improved Quality of Life in Patients with GEP-NETs Treated with 177Lu-DOTATATE
Presenter: Bianka Saravana-Bawan
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4247 - Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals
Presenter: Catherine Bouvier
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4278 - Efficacy and safety of Vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy.
Presenter: Jorge Hernando Cubero
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3657 - Development and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry
Presenter: SHEENO Thyparambil
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract